AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03345485
Drug: Tinostamustine 100mg/m2 over 60min
DrugBank: Tinostamustine (DB15147)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
Trial: NCT03345485
Drug: Tinostamustine 80mg/m2 over 80min
DrugBank: Tinostamustine (DB15147)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 80 minutes on Days (D) 1 and 15 of each 28-day cycle.
Trial: NCT01906944
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine is a local anaesthetic drug belonging to the amino amide group.
Trial: NCT01906944
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone is a long-acting synthetic corticosteroid.
Trial: NCT04497883
Drug: Maribavir (400 mg)
RxNorm normalized name: maribavir
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Non-Hispanic, Caucasian group and Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1.
Trial: NCT04497883
Drug: Maribavir (200 mg)
RxNorm normalized name: maribavir
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Japanese descent group participants will receive 200 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
Trial: NCT04497883
Drug: Maribavir (800 mg)
RxNorm normalized name: maribavir
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Japanese descent group participants will receive 800 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
Trial: NCT02660840
Drug: 0.5 mg Flupentixol film-coated tablet (test treatment)
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose, fasted state, day 1 in period 1 or 2
Trial: NCT02660840
Drug: 1 mg Flupentixol film-coated tablet (test treatment)
RxNorm normalized name: flupenthixol 1 MG
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose, fasted state, day 1 in period 1 or 2
Trial: NCT02660840
Drug: 5 mg Flupentixol film-coated tablet (test treatment)
RxNorm normalized name: flupenthixol 5 MG
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose, fasted state, day 1 in period 1 or 2
Trial: NCT02660840
Drug: 0.5 mg Flupentixol coated tablet (reference treatment)
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose, fasted state, day 1 in period 1 or 2
Trial: NCT02660840
Drug: 1 mg Flupentixol coated tablet (reference treatment)
RxNorm normalized name: flupenthixol 1 MG
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose, fasted state, day 1 in period 1 or 2
Trial: NCT02660840
Drug: 5 mg Flupentixol coated tablet (reference treatment)
RxNorm normalized name: flupenthixol 5 MG
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose, fasted state, day 1 in period 1 or 2
Trial: NCT03373227
Drug: Envarsus
RxNorm normalized name: Envarsus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take once daily Envarsus
Trial: NCT00870714
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
Trial: NCT00870714
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
Trial: NCT00514852
Drug: Carboxymethylcellulose and Glycerin based artificial tear
RxNorm normalized name: carboxymethylcellulose / glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 2 drops into each eye as needed but at least twice daily
Trial: NCT00514852
Drug: Carboxymethylcellulose
RxNorm normalized name: Carboxymethylcellulose
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 2 drops into each eye as needed but at least twice daily
Trial: NCT03750916
Drug: Anlotinib Hydrochloride plus Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
Trial: NCT01610284
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
Trial: NCT00740610
Drug: GS-9450
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
Trial: NCT04554056
Drug: MW05
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Recombinant (yeast secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein injection
Trial: NCT00802815
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 milligrams subcutaneously every week
Trial: NCT00484744
Drug: Avicel (placebo)
RxNorm normalized name: Evicel
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01426542
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.
Trial: NCT02816567
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02816567
Drug: NMBA - cisatracurium
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01246817
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: temsirolimus (standard schedule: 25 mg weekly, by 1-hour i.v. infusion)
Trial: NCT02395601
Drug: CPI-1205
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule inhibitor of the enzyme EZH2
Trial: NCT01508923
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
Trial: NCT01500434
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
Trial: NCT00389402
Drug: saquinavir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00389402
Drug: atazanavir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02536404
Drug: Etrasimod
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01500434
Drug: Thienopyridine
RxNorm normalized name: Phenopyridine
DrugBank: Oxyquinoline (DB11145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
Trial: NCT01125358
Drug: LY2140023
RxNorm normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, twice daily for up to 7 weeks of treatment
Trial: NCT03112096
Drug: [18F]THK-5351
DrugBank: THK-5351 (DB19222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
Trial: NCT02817477
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delivered intranasally using an atomizer
Trial: NCT02817477
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delivered either as an IM injection or a slow IV bolus
Trial: NCT04332835
Drug: Plasma
RxNorm normalized name: Plasma
DrugBank: Plasma protein fraction (human) (DB13968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
Trial: NCT04585061
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle
Trial: NCT04352621
Drug: intranasal ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/kg will be administered intranasally using an atomization device with a maximum dose of 40 mg followed by 6 weeks of rTMS treatment. .
Trial: NCT00065429
Drug: BB-10901
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease.
Trial: NCT02784002
Drug: Ridinilazole
RxNorm normalized name: Ridinilazole
DrugBank: Ridinilazole (DB15308)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02784002
Drug: Fidaxomicin
RxNorm normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00693056
Drug: RX-10100 5mg
RxNorm normalized name: capsaicin 0.25 MG/ML / methylnicotinate 5 MG/ML [Arth-RX]
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg/dose of RX-10100
Trial: NCT00693056
Drug: RX-10100 15mg
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/dose of RX-10100
Trial: NCT03253263
Drug: OHB-607
RxNorm normalized name: OHB
DrugBank: Salicylamide (DB08797)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive intravenous infusion of OHB-607 from birth up to PMA 29 weeks + 6 days.
Trial: NCT00003544
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02724878
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02724878
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00522132
Drug: Artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intravenous application
Trial: NCT00348608
Drug: iodixanol
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00486642
Drug: Bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00486642
Drug: Pazopanib Hydrochloride
RxNorm normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02007512
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.
Trial: NCT02007512
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.
Trial: NCT00502203
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 5 By Vein Over 1 Hour Every 21 Days for 6 Courses
Trial: NCT00502203
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m\^2 By Vein Over 3 Hours Every 21 Days for 6 Courses
Trial: NCT02007512
Drug: Placebo (for enzalutamide)
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
Trial: NCT02007512
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.
Trial: NCT00578760
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 325mg ASA OD for the duration of the cisplatin
Trial: NCT00910299
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
Trial: NCT00910299
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 75 mg oral daily maintenance dose up to 6 months.
Trial: NCT00346424
Drug: Alfimeprase
RxNorm normalized name: Alfimeprase
DrugBank: Alfimeprase (DB04919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01251536
Drug: Dose escalation of cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly
Trial: NCT01251536
Drug: Standard first line treatment with cetuximab + Folfiri
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly.
Trial: NCT03601923
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib belongs to a class of anti-cancer agents known as PARP (poly ADP ribose polymerase) inhibitors. PARP is a protein in the body that repairs damage to DNA (one of the building blocks of a cell). In cells that are rapidly growing, such as cancer cells, blocking repair of DNA may be of benefit, since it will cause the cell to die.~Niraparib will be given at an initial dose of 200mg or 300 mg by mouth once daily depending on the patient's platelet count and weight at the start of the trial.
Trial: NCT00700037
Drug: high-dose atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg/day
Trial: NCT00700037
Drug: low-dose atorvastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg/day
Trial: NCT04134260
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03123406
Drug: Cinacalcet HCl
RxNorm normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.
Trial: NCT00993226
Drug: SABER-Bupivacaine Treatment 1a
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5.0 ml
Trial: NCT00993226
Drug: Placebo SABER-Bupivacaine Treatment 1b
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5.0 ml
Trial: NCT00993226
Drug: Bupivacaine HCl Treatment 1c
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 ml
Trial: NCT02080273
Drug: Colgate Cavity Protection toothpaste
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
Trial: NCT00993226
Drug: SABER-Bupivacaine Treatment 2a
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7.5 ml
Trial: NCT00993226
Drug: Placebo SABER-Bupivacaine Treatment 2b
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7.5 ml
Trial: NCT00993226
Drug: Bupivacaine HCl Treatment 2c
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 ml
Trial: NCT01146457
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active dosage
Trial: NCT01146457
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline Control
Trial: NCT02496780
Drug: novolog insulin
RxNorm normalized name: insulin aspart, human Cartridge [NovoLog]
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3x daily rapid-acting insulin
Trial: NCT00119678
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
Trial: NCT00119678
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
Trial: NCT02496780
Drug: levemir insulin
RxNorm normalized name: insulin detemir Injectable Solution [Levemir]
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: basal insulin once a day
Trial: NCT03376321
Drug: Pimodivir 600 mg
RxNorm normalized name: Pimodivir
DrugBank: Pimodivir (DB14974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
Trial: NCT00119678
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injectable, intravenous, 10 mg/kg, every 28 days
Trial: NCT00313781
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
Trial: NCT00313781
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone is administered at a dose of 5 mg twice daily.
Trial: NCT03960268
Drug: Brodalumab
RxNorm normalized name: Brodalumab
DrugBank: Brodalumab (DB11776)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: interleukin 17 receptor A antagonist
Trial: NCT00272662
Drug: peginesatide
RxNorm normalized name: Peginesatide
DrugBank: Peginesatide (DB08894)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00432549
Drug: Almotriptan
RxNorm normalized name: Almotriptan
DrugBank: Almotriptan (DB00918)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00432549
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03151707
Drug: Nicotinamide Riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide riboside 2g/day for a 2 week duration
Trial: NCT00514501
Drug: Iodofiltic acid I 123
RxNorm normalized name: Iodofiltic acid I 123
DrugBank: Iodofiltic acid I-123 (DB05683)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00240786
Drug: acetaminophen extended release
RxNorm normalized name: acetaminophen Extended Release Oral Tablet
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03148691
Drug: A-101
RxNorm normalized name: YA-101
DrugBank: P-BCMA-101 (DB17371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Solution
Trial: NCT00453414
Drug: Iloprost Inhalation Solution (Ventavis)
RxNorm normalized name: iloprost Inhalation Solution
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no